HER2 testing and correlation with efficacy of trastuzumab therapy.

Oncology (Williston Park) 2002 Oct;16(10):1340-8, 1351-2; discussion 1352, 1355-8

Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

The need for accurate detection of HER2 status is becoming more apparent, as therapeutic decisions are influenced by this information in both the adjuvant and advanced-stage setting. Since the US Food and Drug Administration approved trastuzumab (Herceptin) for the treatment of metastatic breast cancer, the urgency of accurately evaluating HER2 status of breast cancer specimens, in order to identify patients who might benefit from this therapy, has increased. A wide range of assay methods are available for determining HER2 status, but immunohistochemistry followed by fluorescence in situ hybridization (FISH) is the recommended approach for ambiguous cases. FISH is not as widely available and is more costly than immunohistochemistry, but economic modeling shows that it is the most effective (and cost-effective) option.

Download full-text PDF

Source
October 2002
1 Read

Publication Analysis

Top Keywords

her2 status
12
breast cancer
8
benefit therapy
4
identify patients
4
order identify
4
patients benefit
4
therapy increased
4
range assay
4
wide range
4
increased wide
4
specimens order
4
cancer specimens
4
metastatic breast
4
treatment metastatic
4
herceptin treatment
4
cancer urgency
4
urgency accurately
4
status breast
4
her2
4
accurately evaluating
4

Similar Publications